Roche’s new Perjeta regimen shown to help prevent breast cancer recurrence

Roche has announced new clinical data showing the effectiveness of a new Perjeta-based regimen in preventing the recurrence of invasive breast cancer.

Results from the phase III APHINITY study showed adjuvant treatment with a combination of Perjeta, Herceptin and chemotherapy reduced by 19 percent the risk of breast cancer recurrence or death in people with HER2-positive early breast cancer, compared to Herceptin and chemotherapy alone.

At three years, 94.1 percent of people treated with the Perjeta-based regimen did not see their breast cancer return, compared to 93.2 percent treated with Herceptin and chemotherapy. The safety profile of the Perjeta-based regimen, meanwhile, was consistent with previous studies, with a low incidence of cardiac events and no new safety signals.

Data from the APHINITY study will be submitted to global health authorities to support future regulatory applications.

Dr Sandra Horning, chief medical officer and head of global product development at Roche, said: "The Perjeta-based regimen improved upon the high bar set by Herceptin in people with HER2-positive early breast cancer. We look forward to working with global health authorities to bring this treatment option to patients."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.